Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.35 |
| ▸ | SGPL1 | O95470 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6637848 | 0.90 | CTSL (0.37) | CTSLCTSBCTSKS1PR1SGPL1 | |
| SCHEMBL6932786 | 0.67 | CTSL (0.39) | CTSLCTSBCTSKRAB9AKMT2A | |
| SCHEMBL4248138 | 0.67 | KDM4E (0.60) | KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL6643933 | 0.65 | NR1H2 (0.31) | — | |
| SCHEMBL796552 | 0.64 | KDM4E (0.57) | KMT2AKDM4ESMN1; SMN2MEN1 | |
| SCHEMBL8890092 | 0.64 | DRD2 (0.54) | KDM4E | |
| SCHEMBL8890088 | 0.64 | DRD2 (0.54) | KDM4E | |
| SCHEMBL9023290 | 0.63 | KDM4E (0.55) | KDM4ESMN1; SMN2 | |
| SCHEMBL5545060 | 0.62 | KDM1A (0.52) | RAB9AKMT2ANPC1AGTR2HPGD | |
| SCHEMBL5548792 | 0.62 | KDM1A (0.52) | RAB9AKMT2ANPC1AGTR2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | KROIN JULIAN (US) | 2004-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176405-A1 | Methods and compounds for inhibitting MRP1 | ABCC1, ABCB11, ABCB1 | CTSL 1603/4885CTSB 974/4885CTSK 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.